Cho KY, Nomoto H, Nakamura A, Kawata S, Sugawara H, Takeuchi J, Nagai S, Omori Kazuno, Tsuchida K, Miya A, Shigesawa I, Tsuchida K, Yanagiya S, Kameda H, Yokoyama H, Taneda S, Kurihara Y, Aoki S, Nishimoto N, Atsumi T, Miyoshi H.
Improved Time in Range and Postprandial Hyperglycemia with Canagliflozin in Combination with Teneligliptin: Secondary Analyses of the CALMER study.
Journal of Diabetes Investigation, in press
IF: 3.761
Nomoto H, Oba-Yamamoto C, Takahashi Y, Takeuchi J, Nagai S, Yokoyama H, Taneda S, Kurihara Y, Aoki S, Kameda H, Cho KY, Nakamura A, Atsumi T, Miyoshi H.
Effects of switching from liraglutide or dulaglutide to subcutaneous semaglutide on glucose metabolism and treatment satisfaction in patients with type 2 diabetes: protocol for a multi-center, prospective, randomized, open-label, blinded endpoint parallel-group comparison study (the SWITCH-SEMA 1 study).
Diabetes Ther. 2020, in press
IF: 3.179
Kimura Y, Higuchi I, Kobayashi M, Furugen A, Narumi K, Suzuki Y, Miyoshi H, Nakamura A, Atsumi T, Iseki K.
The association between SLC16A11 haplotype and lipid metabolism in Japanese patients with type 2 diabetes.
Drug Metab Pharmacokinet, in press.
IF: 2.772
Miya A, Nakamura A, Cho KY, Nomoto H, Kawata S, Sugawara H, Takeuchi J, Nagai S, Tsuchida K, Omori K, Yokoyama H, Taneda S, Kurihara S, Aoki S, Atsumi T, Miyoshi H.
Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin Journal of Diabetes Investigation, in press
IF: 3.761
Yuno A, Kenmotsu Y, Takahashi Y, Nomoto H, Kameda H, Cho KY, Nakamura A, Yamashita Y, Nakamura J, Nakakubo S, Kamada K, Suzuki M, Sugino H, Inoshita N, Konno S, Miyoshi H, Atsumi T, Sawamura Y, Shimatsu A.
Successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia.
Endocrine Journal, in press.
IF: 1.952 (2019)
Takahashi K, Nakamura A, Furusawa S, Yokozeki K, Sugawara H, Yanagisawa H, Akikawa K, Kikuchi H. Initial dip predicts renal protective effects after the administration of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and chronic kidney disease with normoalbuminuria.
J Clin Transl Endocrinol, 2020 (in press).
IF：なし
Amengual O, Atsumi T.
COVID-19 pandemic in Japan.
Rheumatology International. Accepted, October 29, 2020. In press DOI:
10.1007/s00296-020-04744-9
IF: 1.984
Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Nakamura A, Miyoshi H, Kimura M, Maehara O, Yamada R, Kitagataya T, Yamamoto K, Shigesawa T, Nakamura A, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S and Sakamoto N for the NORTE Study Group.
Tenofovir disoproxil fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection. J Gastroenterol, in press.
IF: 6.132
Favorable effect of sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on nonalcoholic fatty liver disease compared with pioglitazone.
Cho KY, Nakamura A, Omori K, Takase T, Miya A, Yamamoto K, Nomoto H, Kameda H, Taneda S, Kurihara Y, Aoki S, Atsumi T, Miyoshi H Journal of Diabetes Investigation, in press.
IF 3.761
